Samsung BioLogics’ shares down $6bn after accounting furore | Pharmasources.com
We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
I Agree
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Samsung BioLogics’ shares down $6bn after accounting furore

pharmafileMay 03, 2018

Tag: Samsung Biologics , shares down , $6 billion

PharmaSources Customer Service